恒瑞医药将香港发售价格定在区间上限。（IFR国际金融评论）

Core Viewpoint - 恒瑞医药 has set the Hong Kong offering price at the upper limit of the range, indicating strong market confidence and demand for its shares [1] Company Summary - 恒瑞医药 is actively engaging in the Hong Kong market, reflecting its strategic expansion plans and commitment to increasing its international presence [1] - The decision to price at the upper limit suggests robust investor interest and a positive outlook for the company's growth trajectory [1] Industry Summary - The pricing strategy employed by 恒瑞医药 may influence other pharmaceutical companies considering similar market entries, potentially leading to increased competition in the Hong Kong market [1] - The move highlights the growing trend of pharmaceutical companies seeking to tap into Asian markets, particularly Hong Kong, as a means to enhance capital raising efforts [1]